Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

United Therapeutic (NQ: UTHR )

372.85 -0.04 (-0.01%)
Streaming Delayed Price Updated: 3:42 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about United Therapeutic

< Previous 1 2 3 4 5 6 7 Next >
Earnings Outlook For United Therapeutics
Via Benzinga
Decoding 7 Analyst Evaluations For United Therapeutics
Via Benzinga
The Analyst Landscape: 7 Takes On United Therapeutics
Via Benzinga
$100 Invested In United Therapeutics 5 Years Ago Would Be Worth This Much Today
Via Benzinga
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Amphastar hit an all-time high in August 2023 and consolidated. It could be forming the right side of a cup base that started in January. 
Via Investor's Business Daily
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Alkermes develops treatments for neurodegenerative diseases (conditions that damage and destroy parts of the nervous system) and cancer. 
Via Investor's Business Daily
Peering Into United Therapeutics's Recent Short Interest
Via Benzinga
A Look Into United Therapeutics Inc's Price Over Earnings
Via Benzinga
Key Takeaways From United Therapeutics Analyst Ratings
Via Benzinga
The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
Via Benzinga
U.S. Stock: United Therapeutics Corp
United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. 
Via Talk Markets
Here's How Much $1000 Invested In United Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
Keros Therapeutics Stock Meets 80-Plus RS Rating Benchmark
Building your watch list, look for stocks with an 80-plus RS Rating. Keros Therapeutics stock just met that criteria with a new score of 86. 
Via Investor's Business Daily
Innovative Drugmaker Roivant Puts Up Really Healthy Sales Numbers
Roivant stock has an outstanding A- Accumulation/Distribution Rating, showing that institutions such as mutual funds are fairly heavy buyers. 
Via Investor's Business Daily
$100 Invested In This Stock 10 Years Ago Would Be Worth $400 Today
Via Benzinga
Navigating 9 Analyst Ratings For United Therapeutics
Via Benzinga
Ambarella To Rally Around 61%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Biohaven Stock Earns Relative Strength Rating Upgrade
Biohaven stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 88 to 91. 
Via Investor's Business Daily
SpringWorks Therapeutics Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for SpringWorks Therapeutics shows improving technical performance. 
Via Investor's Business Daily
Soviet Code Breaker Jim Simons' Hedge Fund Renaissance Technologies — Ozempic, Wegovy Maker Novo Nordisk Along With Nvidia, Palantir Among Top Holdings
Renaissance Technologies, the hedge fund founded by legendary mathematician and former NSA code breaker Jim Simons, recently disclosed its latest stock holdings in a 13F filing with the U.S. Securities... 
Via Benzinga
ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Why Liquidia Stock Just Reversed Its Seven-Day Sprint And Crashed 38%
The company is hoping to launch a drug that rivals United Therapeutics' Tyvaso DPI. 
Via Investor's Business Daily
Rivian, Chipotle Mexican And Sirius XM Are Among Top 10 Large Cap Losers Last Week (Aug 11-Aug 17): Are The Others In Your Portfolio?
Ten large-cap stocks were the worst performers last week, with TME, MBLY, RIVN, CMG, LINE, SIRI, HSY, BAX, BR, and UTHR all seeing declines. 
Via Benzinga
NASDAQ:UTHR is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
UNITED THERAPEUTICS CORP (NASDAQ:UTHR) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
3 Biotech Stocks on Track for 50% Returns (or More) by 2028
Investors should consider snapping up these high potential biotech stocks that could return 50% or more by 2028! 
Via InvestorPlace
UTHR Stock Earnings: United Therapeutics Misses EPS, Beats Revenue for Q2 2024
UTHR stock results show that United Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
United Therapeutics Stock Skids On Mixed Second-Quarter Results
The company's earnings came in far below expectations, though sales easily beat. 
Via Investor's Business Daily
The 3 Best 3D Bioprinting Stocks to Buy Now
These are three of the best 3D bioprinting stocks to buy as the technology begins to hit its stride in the health care sector. 
Via InvestorPlace
Beam Therapeutics Stock Earns RS Rating Jump To 85
On Wednesday, Beam Therapeutics stock now clears the 80 or higher Relative Strength Rating threshold, with a jump from 65 to 85. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.